Three abstracts accepted by ASH with two poster presentations Geneva, Switzerland and Amsterdam, The Netherlands, 3 November 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San […]
Roginolisib is in development for solid and hematologic malignancies including uveal melanoma Geneva, Switzerland and Amsterdam, The Netherlands, 31 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that the US Food and Drug Administration (FDA) has granted permission to proceed […]
Amsterdam, The Netherlands and Geneva, Switzerland, 19 October 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces publication of new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359. Read […]
There’s an increasing focus on using drugs to modify the tumour microenvironment, reducing immunosuppression and breaking down the barrier of fibrotic scar tissue that blocks many therapies. Optimum Strategic Communications’ Richard Staines talked to our client iOnctura, about the Company’s plans to use an autotaxin inhibitor to remove this obstacle. Scientists are looking at a […]
Geneva, Switzerland and Amsterdam, The Netherlands, 1 June 2023 – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, today announces that it will be presenting at leading scientific conferences throughout June 2023. Read more…
